Prozac Weekly, the once-a-week 90 mg delayed-release capsule, was discontinued for business reasons, not because of any safety or effectiveness concerns. The FDA explicitly confirmed that the decision was not related to the drug’s safety profile. The real story behind its disappearance is a mix of patent strategy, generic competition, and market economics.
A Patent Strategy That Didn’t Pan Out
To understand why Prozac Weekly existed in the first place, you need to understand the timeline. Prozac (fluoxetine) was first approved in 1987 and became one of the most widely prescribed antidepressants in history. Its patent expired in August 2001, opening the floodgates for cheap generic versions of the standard daily pill.
Eli Lilly released Prozac Weekly just five months before that patent expiration. This was not a coincidence. Under the Hatch-Waxman Act, pharmaceutical companies can get an additional three years of market exclusivity for a new formulation of an existing drug. Launching a reformulated version right before generics arrive is a common industry strategy to shift patients onto a product that still has patent protection. Researchers have specifically identified Prozac Weekly as the first SSRI reformulation to use this approach.
The strategy had limited success. Once generic fluoxetine hit the market in 2001, daily pills became available for a fraction of the cost. Most patients and insurers had little reason to pay brand-name prices for a weekly capsule when a daily generic worked just as well. Without enough market demand to justify continued production, the product was eventually pulled.
Why Weekly Dosing Was Possible
Fluoxetine is unusual among antidepressants because it stays in your body for a very long time. After you’ve been taking it regularly, the drug itself has a half-life of 4 to 6 days. Its active byproduct, which your liver produces as it processes the medication, sticks around even longer, with an average half-life of about 9 days. That means the medication and its active byproduct are still working in your system well beyond a single day.
This long duration is what made a once-weekly formulation scientifically feasible. The 90 mg delayed-release capsule slowly released a larger dose that could maintain therapeutic levels for a full week. Clinical trials showed this approach kept depression in remission for up to 25 weeks when patients had first stabilized on the standard daily 20 mg dose for 13 weeks.
No Generic Replacement Exists
If you’re looking for a generic version of Prozac Weekly, it doesn’t exist. The FDA never approved a generic equivalent of the 90 mg delayed-release capsule, and the formulation itself has been fully discontinued. No manufacturer currently produces it.
This means the weekly dosing option is simply unavailable. Patients who were on Prozac Weekly, or who might have benefited from it, are limited to daily fluoxetine, which remains widely available as an inexpensive generic in doses ranging from 10 mg to 60 mg. The original Prozac label noted that patients who weren’t maintaining well on the weekly version could switch back to daily dosing, though it didn’t specify a particular waiting period for that reverse transition.
What This Means for Daily Fluoxetine
The discontinuation of Prozac Weekly has no bearing on the safety or availability of daily fluoxetine. The daily version remains one of the most commonly prescribed antidepressants worldwide, available as a generic for very low cost. Its long half-life, the same property that made weekly dosing possible, also makes it more forgiving than many other antidepressants if you occasionally miss a dose. A single missed day is unlikely to cause the withdrawal-like symptoms that can occur with shorter-acting medications.
The convenience factor was the main appeal of the weekly capsule. Taking one pill per week instead of seven is genuinely easier for some people, particularly those managing multiple medications or struggling with daily adherence. That convenience simply couldn’t compete with the price difference once generics arrived, and no manufacturer has found it worthwhile to bring the formulation back.